secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2026-06-16T20:02:56+00:00
Accession:  0000879407-26-000050
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead appoints Dr. Matt Cohen to board of directors
-------------------------------------------------------

- Appointed Dr. Matt Cohen, M.D., M.B.A., as director effective June 12, 2026.
- Cohen is Managing Director at Vida Ventures; previously lead healthcare investor at JPMorgan for ~20 years.
- Received standard non-employee director compensation plus sign-on RSU grant of $887,000 vesting over three years.
- No family relationships or arrangements with any other director or officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000087940726000050/0000879407-26-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000087940726000050/arwr-20260612.htm
  HTML page:      https://secwatch.observer/filing/0000879407-26-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer